Arlene Sharpe, right, watches as Graduate Student Emily Gaudiano removes a rack of samples of cancer cell lines from mice from a freezer at the Sharpe Laboratory at Harvard Medical School. In second grade, in Gary, Indiana, her science fair project showing the lima bean's stages of germination won a special note from the school principal. She still has it today, at age 65.
She grew particularly curious about the workings of disease. Her mother was sick for most of her childhood. That was back in the ‘70s, but Strominger still remembers her fondly."Arlene is one of my favorites," he says,"I think because she's such a modest person." And so was born what Freeman calls “the family business.” He's now a professor of medicine at the Dana-Farber Cancer Institute and Harvard. The “family business” was trying to understand the genes that control the immune system. Freeman would clone them, and Sharpe would use a tool that was new back then, called gene knockout, to eliminate them and see what they did.
"Scientifically, the understanding of these negative receptor molecules, these brakes in the immune system, was hugely important," says Manchester University immunology professor Daniel Davis, author of".""And medically, it became hugely important when it was realized that you could unleash the immune response against cancer."
"You know, I never say that I'm cured, I always say that I'm healed," he says. He has personally thanked Sharpe and Freeman for his reprieve, he says,"because my healing came from God, but he blessedwith the technology and the idea of how to put all this together so that it would bless other people all around the world."
WBUR Fantastic
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Merck's Keytruda no better than chemo as a first-line treatment for gastric cancer, according to Phase 3 study resultsMerck & Co. Inc. said Friday that a Phase 3 trial evaluating Keytruda as a first-line treatment for gastric cancer failed to show improvement in patients' overall or progression-free survival when compared with chemotherapy. Shares of the drugmaker were down 0.05% in premarket trade. An earlier Phase 3 study looking at Keytruda as a second-line treatment for gastric cancer also failed to show a survival benefit, though the Food and Drug Administration did approve the drug in 2017 as a third-line treatment for patients with advanced gastric cancer. Keytruda is currently used for many other cancer indications, including treating certain subsets of patients with melanoma, lung cancer, Hodgkin lymphoma and cervical cancer, among many others. Shares of the pharmaceutical giant have fallen 0.1% in the year to date, while the S&P 500 has gained 16.7%.
Source: MarketWatch - 🏆 3. / 97 Read more »
Forbes Media - Jobs: Assistant Editor, Healthcare & Science - Apply online\u003cp\u003eForbes Media seeks an \u003cstrong\u003eAssistant Editor\u003c/strong\u003e to support the Forbes \u003cstrong\u003eHealthcare \u0026amp; Science\u003c/strong\u003e beat in our Jersey City, NJ, office. Assistant Editors are the linchpin of the Forbes newsroom. This candidate will be assigned to healthcare, science, pharma and biology content, working at the intersection of editorial (editors, staff writers and outside contributors) and internal teams including social, product and analytics. This person will help to organize Forbes' annual Healthcare Summit.\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003cstrong\u003eRESPONSIBILITIES\u003c/strong\u003e\u003c/p\u003e\u003cul\u003e \u003cli\u003eWork on front lines of editorial coverage. Read and edit (as appropriate) the content stream on the channel and overall site and monitoring any issues with the CMS\u003c/li\u003e \u003cli\u003eAssist editors to find, recruit, and set up new contributors. Train and support contributors on how to use and optimize Forbes publishing tools.\u003c/li\u003e \u003cli\u003eStay on cutting edge of technology, specifically the venture capital and cybersecurity industry; monitor breaking news and must-read sites, social streams, trade press and more.\u003c/li\u003e \u003cli\u003eCollaborate with editors to find original angles to news and enterprise stories; follow up with reporting and writing stories or pitching stories to contributors.\u003c/li\u003e \u003cli\u003eParticipate in larger Forbes projects, including 30 Under 30 as a reporter and writer. Ideal candidate is expected to pitch, write regular stories for the site and/or magazine. Member of fact checking pool for the magazine.\u003c/li\u003e \u003cli\u003eWork with audience development and other internals teams monitor optimize traffic.\u003c/li\u003e \u003cli\u003eCreate original content for Forbes platforms outside the site, including social media, podcasts and newsletters, as well as live events.\u003c/li\u003e \u00
Source: Forbes - 🏆 394. / 53 Read more »